Mrsa | Despite Generic Vancomycin's Continued Dominance Of The MRSA Market, Branded Agents Cubicin And Zyvox Emerge As ...


BURLINGTON, Mass., May 6, 2014 /PRNewswire/ –Decision Resources Group finds that overall, infectious disease (ID) specialists and non-ID physicians (critical care and internal medicine specialists) prefer the branded agents Cubist’s Cubicin (daptomycin) and Pfizer’s Zyvox (linezolid), respectively, when treating methicillin-resistant Staphylococcus aureus (MRSA) infections in the hospital. Nearly half of surveyed ID specialists indicate they prefer Cubicin for treatment of bloodstream infections and/or endocarditis due to MRSA, whereas less than 20 percent of non-ID specialists indicate preference for Cubicin in these indications. However, both physician groups prefer Zyvox for nosocomial pneumonia due to MRSA, likely driven by post-marketing studies demonstrating its clinical superiority over vancomycin. Despite varying drug preferences between the two physician groups, vancomycin remains their most prescribed antibiotic for MRSA infections by both ID specialists and non-ID physicians, driven by physician familiarity, unrestricted formulary access and lower cost.


Other key findings from the U.S. Physician and Payer Forum report entitled MRSA Infections: How Will U.S. Physician and Payer Receptivity to Novel Therapies Influence the Hospital-Treated Infections Market? :

Increasing competition in the MRSA market: The MRSA market, particularly the complicated skin and skin structure infection (cSSSI) segment, will become increasingly crowded as three new antibiotics may launch in the United States in 2014. Cubist, Durata Therapeutics and The Medicines Company have all filed new drug applications and marketing authorization applications for tedizolid, dalbavancin (Dalvance) and oritavancin, respectively.

Impact of generic linezolid on uptake of Cubist’s Sivextro (tedizolid): Among the majority of hospital pharmacy directors who indicated they would include tedizolid on formulary, only 15 percent indicated they would not include it if generic linezolid (priced at a 25 percent discount to branded Zyvox) were available, suggesting that pharmacy directors consider tedizolid sufficiently differentiated from linezolid to merit formulary inclusion of both agents.

Benefits of interchangeable IV and oral formulations: According to


Click here to view rest of article from original site


Facebook Twitter Email